Faron Pharmaceuticals Oy Director/PDMR Shareholding (5371T)

TIDMFARN

RNS Number : 5371T

Faron Pharmaceuticals Oy

13 October 2017

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR")

The notification below is being made in accordance with the requirements of the EU Market Abuse Regulation with reference to Dr Frank Armstrong's participation in the Placing and Subscription announced by the Company on 11 October 2017.

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
--------------------------------------------------------------------------- 
 1      Details of the person discharging managerial 
         responsibilities/person closely associated 
-----  -------------------------------------------------------------------- 
 a.     Name                           Frank Armstrong 
                                      ------------------------------------- 
 2      Reason for 
         notification 
-----  -----------------------------  ------------------------------------- 
 a.     Position/Status                Person discharging managerial 
                                        responsibilities 
 
                                        Non-executive Chairman 
-----  -----------------------------  ------------------------------------- 
 b.     Initial notification/          Initial Notification 
         Amendment 
-----  -----------------------------  ------------------------------------- 
 3      Details of the issuer, emission allowance 
         market participant, auction platform, auctioneer 
         or auction monitor 
       -------------------------------------------------------------------- 
 a.     Name                           Faron Pharmaceuticals Oy 
-----  -----------------------------  ------------------------------------- 
 b.     LEI                            7437009H31TO1DC0EB42 
-----  -----------------------------  ------------------------------------- 
 4      Details of the transaction(s): section to 
         be repeated for (i) each type of instrument; 
         (ii) each type of transaction; (iii) each 
         date; and (iv) each place where transactions 
         have been conducted 
-----  -------------------------------------------------------------------- 
 a.     Description                    Ordinary shares 
         of the financial 
         instrument,                    ISIN: FI4000153309 
         type of instrument 
 
         Identification 
         Code 
-----  -----------------------------  ------------------------------------- 
 b.     Nature of the                  Subscription 
         transaction 
-----  -----------------------------  ------------------------------------- 
 
 c.     Price(s) and                    Price(s)          Volume(s) 
         volume(s) 
-----  -----------------------------   ----------------  --------------- 
                         800 GBPp                          1,250 
   ----------------------------------------------------  --------------- 
 
 d.     Aggregated 
         information 
                                         1,250 
         - Aggregated 
         Volume                          10,000 GBP 
 
         - Price 
-----  -----------------------------  ------------------------------------- 
 e.     Date of the                    11 October 2017 
         transaction 
-----  -----------------------------  ------------------------------------- 
 f.     Place of the                   Off-exchange transaction 
         transaction 
-----  -----------------------------  ------------------------------------- 
 
 

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

[e-mail]

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

Westwicke Partners, IR (US)

Chris Brinzey

Phone: [phone]

E-Mail: [e-mail]

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: [phone]

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: [phone]

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKNDQOBDKFKD

(END) Dow Jones Newswires

October 13, 2017 04:00 ET (08:00 GMT)